• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Lipoxygenase-derived eicosanoids in myocardial ischaemia-reperfusion injury: the role of sensory C-fibres and TRPV1 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Lipoxygenase-derived eicosanoids in myocardial ischaemia-reperfusion injury: the role of sensory C-fibres and TRPV1
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Lipoxygenase-derived eicosanoids in myocardial ischaemia-reperfusion injury: the role of sensory C-fibres and TRPV1
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Lipoxygenase-derived eicosanoids in myocardial ischaemia-reperfusion injury: the role of sensory C-fibres and TRPV1

    View/Open
    GODDARDLipoxygenase-derived2010.pdf (2.398Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    It is well established that the 12-lipoxygenase (12-LOX) pathway of arachidonic acid (AA) metabolism is stimulated within the myocardium by episodes of ischaemia, and there is considerable evidence showing that eicosanoids derived via this pathway protect against the damaging effects of myocardial ischaemia-reperfusion (I/R) injury. Recent evidence suggests that transient receptor potential vanilloid receptor 1 (TRPV1), expressed on sensory C-fibres, may play an important protective role against myocardial I/R injury; and in neurones, the 12-LOX metabolite of AA 12(S)-hydroperoxyeicosatetraenoic acid [12(S)-HpETE], has been proposed as an endogenous ligand for TRPV1. However, whether 12(S)-HpETE underlies TRPV1 channel activation during myocardial I/R is unknown. Treatment of isolated Langendorff rat hearts with 12-LOX/AA significantly attenuated I/R injury (~40% inhibition of infarct size), an effect reversed by the 12-LOX inhibitor baicalein or by chemical desensitisation of local C-fibre afferents in vivo using capsaicin. Both 12(S)-HpETE and AA caused dose-dependent coronary vasodilatation (~pEC50s of 18.2 and 6.9, respectively) that was profoundly suppressed by the TRPV1 antagonist capsazepine, or in hearts of TRPV1 knockout mice compared to wild-type mice, or by treatment with the calcitonin gene-related peptide (CGRP) receptor antagonist, CGRP8-37. I/R in vitro reduced expression of myocardial TRPV1 protein, whereas in vivo, TRPV1 protein expression in the heart and dorsal root ganglia (DRG) increased, and DRG TRPV1 messenger ribonucleic acid levels decreased – suggesting that whilst TRPV1 protein may be down-regulated during I/R in vitro, when neurones innvervating the heart are associated with their cell bodies, TRPV1 expression may be increased, possibly under the control of neurotrophic factors. Together, the findings from this thesis identify a novel 12-LOX/AA/TRPV1 pathway activated and up-regulated during myocardial I/R injury, providing an endogenous damage-limiting mechanism – the targeting of which may prove useful in treating myocardial infarction or protecting against I/R injury associated with common surgical procedures including cardiac transplantation.
    Authors
    Goddard, Alison
    URI
    https://qmro.qmul.ac.uk/xmlui/handle/123456789/526
    Collections
    • Theses [3834]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.